



# **Veloxis Pharmaceuticals A/S 2016 First Quarter Report**

## **Investor Conference**

**Craig A. Collard, President and CEO**

**Johnny Stilou, CFO**

**Alastair McEwan, COO**

19-May-2016, 3pm CET

### Dial-in Numbers:

Denmark +45 32 71 16 59

UK +44(0) 20 3427 1910

USA +1 646 254 3362

Access Code 8446996

# Forward-Looking Statements

---

This presentation contains forward-looking statements. All statements other than statements of historical facts included in this presentation are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control.

Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will” and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding potential future regulatory approvals for ENVARSUS XR® (formerly LCP-Tacro™), and commercial forecasts are considered forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate.

Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to our ability to obtain regulatory approval for, and commercialize, ENVARSUS XR®; our ability to hire and retain personnel in a competitive industry; our reliance on third parties to manufacture and distribute ENVARSUS XR®; competition from existing therapies and therapies that are currently under development, including Prograf® (tacrolimus), Advagraf® /Astagraf XL® (tacrolimus), generic tacrolimus products, and Nulojix® (belatacept); whether we are able to obtain additional financing, if needed; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date hereof. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.



# Agenda

---

- Veloxis Q1 2016 Highlights
- Financials Q1 2016
- Q & A

# Q1 2016 Highlights

---

- Commercial launch in the U.S.
  - Envarsus XR is indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations
- Envarsus XR achieved Net Revenues of \$1.5 Million
- U.S. commercial activities in the process of being moved to the U.S. with offices in New Jersey and North Carolina
- EU commercialization activities progressing successfully with over 650 patients on product through end of March
- Alastair McEwan appointed as Chief Operating Officer
- 5-Year Term Loan and security agreement with Lundbeckfond invest A/S and Novo A/S for up to \$20 Million in financing

# Financial Results



## First quarter 2016 results in line with expectations

USD '000	First three months		Full year	Outlook
	2016	2015	2015	2016
Revenue	1,500	647	2,103	
Production costs	(764)	(626)	(2,250)	
Gross profit	736	21	(147)	
Sales and marketing	(3,806)	(1,484)	(9,840)	
Research and development	(2,224)	(3,137)	(11,345)	
General and Administration	(1,627)	(2,421)	(7,968)	
Operating loss	(6,921)	(7,021)	(29,300)	(17,600) - (23,400)
Net loss	(7,109)	(4,077)	(26,179)	(17,600) - (23,400)
Cash position ending	6,650	33,642	15,763	

**Q & A**

**Thank you for your attention!**

